Ardelyx

ARDX Small Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$5.94

-2.78% today

52W: $3.21 – $8.40

52W Low: $3.21 Position: 52.6% 52W High: $8.40

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

11.38x

Forward Price/Earnings

P/S Ratio

3.58x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$1.5B

Market Capitalization

Revenue Growth

7.8%

YoY Revenue Growth

Profit Margin

-15.12%

Net profit margin

ROE

-36.21%

Return on Equity

Beta

0.66

Market sensitivity

Short Interest

9.99%

% of float sold short

Avg. Volume

4,646,508

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

10 analysts

Avg. Price Target

$16.10

+171.04% upside

Target Range

$13.00 – $19.00

About the Company

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 489 Exchange: NGM